Tandem Diabetes Care Inc.

Tandem's product development is overseen by its executive team under CEO John Sheridan (as of 2025, the CEO is John Sheridan, per the company's 2024 proxy statement). The R&D team includes engineers focused on hardware, embedded software, and algorithm design. The company does not publicly name a single chief medical officer or head of product.

Control-IQ+ uses a model-predictive control algorithm that adjusts basal insulin every five minutes based on CGM trends and also delivers automatic correction boluses when glucose is predicted to exceed 180 mg/dL. Medtronic's SmartGuard uses a simpler threshold-suspend approach. Clinical data from a 2023 study showed Tandem's system improved time-in-range by about 2.6 hours per day compared to a control group (per Beck RW et al., Diabetes Technology & Therapeutics, 2023).

No. Tandem Diabetes Care is a publicly traded corporation (TNDM) with no disclosed family office, venture arm, or investment subsidiary. Its capital structure consists of common equity held by institutional and retail shareholders.

Tandem sells directly in the US and through distributors in select international markets, including Canada, the UK, Germany, and Australia (per company 2023 Annual Report). The company also operates a subsidiary in Germany. It does not disclose distributor names or country-level revenue.

Yes. In 2022, Tandem issued an urgent medical device correction for the t:slim X2 regarding a potential occlusion alarm issue. In 2024, the FDA issued a Class I recall for certain Tandem Mobi pump charging cables due to fire risk (per FDA recall database, January 2024). No deaths were associated with either event.

Tandem competes with Medtronic (MiniMed series), Insulet (Omnipod), and Roche (Accu-Chek) in the insulin pump market. It also faces competition from emerging startups such as EOFlow (now under Medtronic) and Beta Bionics (iLet pump). In the CGM space, Tandem partners with Dexcom and Abbott rather than competing.

Tandem does not separately break out hardware versus consumables revenue in its financial filings. However, the company's 2023 10-K notes that pump shipments generate upfront revenue and recurring revenue from infusion sets, reservoirs, and CGM sensors sold through its channel. The majority of revenue in 2023 came from pump sales and supplies combined ($748M total revenue).